Synthesis and composition of amino acid linking groups conjugated to compounds used for the targeted imaging of tumors
US-2016339122-A1 · Nov 24, 2016 · US
US10011602B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10011602-B2 |
| Application number | US-201314413164-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 5, 2013 |
| Priority date | Jul 6, 2012 |
| Publication date | Jul 3, 2018 |
| Grant date | Jul 3, 2018 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention provides a ligand which binds to MR1 wherein said binding results in binding of the MR1 to MAIT cells.
Opening claim text (preview).
The invention claimed is: 1. A method of detecting the presence of MAIT cells in a biological sample from a subject, the method comprising the steps of a) contacting the biological sample with antigen presenting cells expressing MR1 bound to a ligand or a soluble form of MR1 bound to a ligand, under conditions that would allow binding of the MR1 or the soluble form of MR1 with MATT cells present in the sample, wherein the ligand is a compound selected from the group consisting of rRL-6HM, rRL-6AM, RL-6M, RP-5PA, 6-formyl pterin, acetyl 6-formyl pterin, 6-methyl-7-hydroxy-8-ribityl lumazine, and 6-,7-dimethyl-8-Ribityl Lumazine; and b) detecting the presence of MAIT cell bound MR1 or MAIT cell bound soluble form of MR1 in the biological sample, thereby detecting the presence of MAIT cells in a biological sample from a subject. 2. The method according to claim 1 , wherein the ligand is rRL-6HM. 3. The method of claim 1 , wherein the biological sample is a biological fluid. 4. The method of claim 1 , wherein the biological sample is a cell sample. 5. The method of claim 1 , wherein the biological sample is a tissue sample. 6. The method of claim 3 , wherein the biological fluid is serum, lymph, or blood. 7. The method of claim 5 , wherein the tissue sample is a bone marrow or a tissue biopsy sample including mucosal tissue. 8. The method of claim 7 , wherein the tissue biopsy sample is from the gut, gut lamina propria, or lungs. 9. The method of claim 1 , wherein the MR1 is a human, primate, or mouse MR1 polypeptide. 10. The method of claim 8 , wherein the MR1 polypeptide comprises SEQ ID NO: 1 or SEQ ID NO: 4. 11. The method of claim 1 , wherein the subject is a human.
MHC-molecules, e.g. HLA-molecules · CPC title
with a nitrogen atom directly attached in position 2 · CPC title
White blood cells · CPC title
with an oxygen atom directly attached in position 4 · CPC title
MHC-molecules, e.g. HLA-molecules · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.